The Next Wave in Adaptive Biomedical Innovation:
Advancing Platform Trials into End to End Rapid Learning Systems
Hosted by the NEWDIGS Initiative at the MIT Center for Biomedical Innovation
From siloed to ecosystem-driven innovation
•
Applying adaptive biomedical innovation
•
Scaling platform clinical trials
•
Connecting pre- and post-market learning
•
Designing disease ecosystems
•
Driving sustainable, patient-centered innovation
December 12–13, 2017
Massachusetts Institute of Technology
Next Wave Forum video playlist
Dr Don Berwick, President Emeritus and Senior Fellow, Institute for Healthcare Improvement, could not join the Forum in person, but his recorded remarks perfectly summarized the challenges and importance of creating a learning system for biomedical innovation.
Snapshots of the Next Wave Forum. Credit: David Parnes Photography
Featuring
Janet Woodcock, MD
Director, Center for Drug Evaluation and Research at FDA
Gerald Dal Pan, MD, MHS
Director, Office of Surveillance and Epidemiology at FDA
Laura Esserman, MD, MBA
Director, UCSF Carol Franc Buck Breast Care Center
Jonathan Gruber, PhD
Ford Professor of Economics, MIT
Trent Haywood, MD, JD
Chief Medical Officer, Office of Clinical Affairs, Blue Cross Blue Shield Association
Sandy Pentland, PhD
Director, MIT Human Dynamics Laboratory
Sebastian Schneeweiss, MD, ScD
Professor of Medicine and Epidemiology, Harvard Medical School
Mark Cziraky, PharmD
Co-founder and Vice President of Research, HealthCore, Inc.
Additional esteemed speakers
Brian Alexander, MD, MPH
Disease Center Leader, Radiation Oncology, Center for Neuro Oncology, Dana-Farber Cancer Institute
Derek C. Angus, MD, MPH, FRCP
Chair, Department of Critical Care Medicine, University of Pittsburgh
Naomi Aronson, PhD
Executive Director of Clinical Evaluation, Innovation, and Policy, Blue Cross and Blue Shield Association
Anna D. Barker, PhD
Co-Director, Complex Adaptive Systems
Professor, School of Life Sciences
Director, National Biomarker Development Alliance (NBDA)
Arizona State University
Don Berwick, MD, MPP
President Emeritus and Senior Fellow, Institute for Healthcare Improvement
Mathieu Boudes, PhD
Operations and Projects Manager, EURORDIS
Nick Crabb, PhD
Programme Director, Scientific Affairs at NICE
Edward Connor, MD, MBE, FAAP
Chairman and President, Institute for Advanced Clinical Trials for Children
Michael A. Cusumano, PhD
Sloan Management Review Distinguished Professor of Management, MIT
Jonathan M. Davis, MD
Director of the CTSA Trial Innovation Network Center at the CTSA Hub
Tufts CTSI; Floating Hospital for Children at Tufts Medical Center
Kourtney Davis, PhD, MSPH
Global Head of Real World Data and Analytics, GlaxoSmithKline 
Anne-Virginie Eggimann, MSc
Vice President, Regulatory Science, bluebird bio, Inc.
Hans-Georg Eichler, MD, MSc
Senior Medical Officer, European Medicines Agency
John Ferguson, MD
Head, Genzyme PV Unit
Global Pharmacovigilance and Epidemiology
Sanofi US
R. John Glasspool
Financing and Reimbursement of Cures in the US (FoCUS) Project Senior Advisor, CBI, MIT
Gigi Hirsch, MD
Executive Director, Center for Biomedical Innovation, MIT
Eric Klopfer, PhD
Director, Scheller Teacher Education Program & The Education Arcade, MIT
Peter Kolchinsky, PhD
Portfolio Manager & Managing Director, RA Capital Management, LLC
Marina Kozak, PhD
Project Officer, OS/ASPR/BARDA, U.S. Department of Health and Human Services
Denis Lacombe, MD, MSc
Director General, EORTC
Kay Larholt, ScD
Director of Integrated Knowledge Solutions, WISDOM Program, CBI, MIT
Laurice Levine, MA
Patient Advocate and Independent Medical Consultant
Robyn Lim, PhD
Senior Science Advisor, Health Products and Food Branch, Health Canada
Victoria Manax, MD
Chief Medical Officer, Pancreatic Cancer Action Network
Hilary M. Malone, PhD
Chief Regulatory Officer, Sanofi
Newell McElwee, PharmD, MSPH
Vice President, Health Economics and Outcomes Research, Boehringer-Ingelheim
Carole Mitnick, ScD
Associate Professor of Global Health and Social Medicine, Harvard Medical School
Jane Perlmutter, PhD, MBA
President and Founder, Gemini Group
Eleanor Perfetto, PhD, MS
Senior VP, Strategic Initiatives, National Health Council & Professor of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy
Edmund Pezalla, MD, MPH
Independent consultant; formerly Aetna
William B Rouse, PhD
Alexander Crombie Humphreys Chair in Economics of Engineering, Stevens Institute of Technology
Eric Rubin, MD
Vice President, Therapeutic Area Head, Oncology Early Development, Merck & Co., Inc.
Susan Schaeffer
Editor, BioCentury
William E. Smoyer, MD
Director, Center for Clinical and Translational Research, Nationwide Children’s Hospital
Richard S. Strauss, MD
Senior Director, Clinical Research, The Janssen Pharmaceutical Companies
Mark Trusheim, MS
President, Co-Bio Consulting
Luc Truyen, MD, PhD
Global Head, Development and External Affairs, Neuroscience, The Janssen Pharmaceutical Companies
Including senior thought leaders from
December 12th morning:
Innovating how we innovate
Michael Cusumano
Outside-in learning: Insights from the evolution of industry platforms in other commercial verticals
December 12 afternoon:
Catalyzing next generation platform trials
Reception and poster session
December 13 morning:
Connecting data and evidence across the product lifecycle
Welcome and introduction
Fireside Chat: Gerald Dal Pan, Trent Haywood and Hilary Malone, Moderated by Hans-Georg Eichler
Bridging the chasm: Connecting pre- and post-market learning
December 13 afternoon:
Advancing from silo-driven to ecosystem-driven innovation
William Rouse
Innovation in Fragmented Health Ecosystems
Gigi Hirsch
Action Plan
Details and Registration
The Next Wave in Adaptive Biomedical Innovation:
Advancing Platform Trials into End-to-End Rapid Learning Systems
December 12–13, 2017
Boston Marriott Cambridge
Cambridge, Massachusetts
Sponsored by
Sector leaders
Forum Sponsor
and Commons Hosts
Hosted by the MIT Center for Biomedical Innovation
The MIT Center for Biomedical Innovation integrates the Institute’s technical, scientific, and management expertise to solve complex biopharmaceutical challenges and improve the impact of biomedical innovation on society.
Cross-stakeholder collaboration drives CBI activity. Cutting-edge MIT research is complemented by expertise from industry, public agencies, and patient advocacy to develop scalable and sustainable solutions for problems in biopharmaceutical r&d, manufacturing, safety, and financing.
The Center advances practice through new knowledge and through real-world initiatives like NEW Drug Development ParaDIGmS (NEWDIGS) and The Biomanufacturing Project (BioMAN). Altogether, these activities bring parties together for mutual advantage and create system-scale healthcare impact.